Roche, obesity pill trial
Healthy Returns: How competitive can Roche be in the weight loss drug market?
Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health market with acquisition of Veri.
Roche shares drop on side effects result in early-stage obesity pill trial
Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans. Roche shares were down 4% at the open at 0700 GMT after the company presented late on Wednesday details on the trial.
Roche Not Alarmed by Obesity Drug’s Side Effects, R&D Head Says
Roche Holding AG said it isn’t concerned about side effects in a small study of a weight-loss shot, after details about the trial sent shares tumbling on Monday.
Obesity Pill Race Heats Up as Novo, Roche and Terns Share Data
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, but the comparisons are rife with confounding variables, leaving analysts unsure about where to place their bets.
Roche says early-stage obesity pill results were based on just six patients
Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.
Roche Falls as Side Effects Data for Obesity Drug Raises Concern
Shares of Roche Holding AG fell after a poster highlighted side effects in an early-stage study of the Swiss pharmaceutical company’s experimental obesity medicine.
Roche Shares Slump on Oral Weight-Loss Drug Candidate Side Effects
Roche’s stock fell after new data from an early-stage clinical trial of its closely watched oral weight-loss drug candidate prompted analysts to question the company’s potential to quickly enter a booming obesity market.
Roche shares knocked by concern over side effects in obesity pill trial
FRANKFURT (Reuters) -Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes was linked to an elevated rate of temporary side effects in its initial test phase on humans.
Roche Obesity Pill Study: What Are the Side Effects?
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
Roche's Manu Chakravarthy talks weight loss drug trial results
Manu Chakravarthy, Roche, joins 'Fast Money' to talk its weight loss drug trial results. Snap poll after debate reveals state of presidential race between Trump and Harris Save Money On Steak With This Easy Costco Shopping Tip If you always use these 6 phrases,
Roche shares slip on obesity drug trial side effects
Shares of Roche (SIX:RO) fell on Thursday following reports from an early-stage trial of an obesity medication, which showed a high rate of temporary side effects. At 4:44 am (0844 GMT), Roche was trading 4% lower at
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Roche Holdings AG (OTC:RHHBY) released positive topline results of the phase 3 CENTERSTONE study of Xofluza (baloxavir ...
Drug Store News1d
FDA approves Roche’s Ocrevus Zunovo with Halozyme’s Enhanze drug delivery technology
Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...
ENDPOINTS NEWS5d
Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets
Roche has already budgeted for future commercial manufacturing builds and established a network of contract manufacturers as ...
Roche's Xofluza Reduces Influenza Transmission In Phase III Study
Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...
Benzinga.com2d
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Xofluza was well tolerated with no new safety signals identified. Every year, seasonal influenza infects an estimated one billion people and causes up to 650,000 deaths globally. On Thursday ...